Skip to content

Evaluation of Convalescent Plasma Therapy for COVID-19 Patients

Evaluation of Convalescent Plasma Therapy for COVID-19 Patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200503047281N1
Enrollment
40
Registered
2020-07-25
Start date
2020-09-22
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: 20 patients are in the severe stage of the disease who receive plasma therapy with intravenous injection dose twice (200 ml per dose) and in addition to routine med

Sponsors

Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: age between 20 to 60 years old

Exclusion criteria

Exclusion criteria: People with a history of other immune, genetic or infectious diseases other than corona Individual suspended but negative for clinical standard covid-19 test

Design outcomes

Primary

MeasureTime frame
Percentage of patients discharged from the intensive care unit and hospital. Timepoint: Measurement of all standard clinical signs of the disease before the start of plasma therapy and after the start of each injection of plasma over specific intervals of up to one year (if surviving). Method of measurement: Patient file information.

Secondary

MeasureTime frame
Patient mortality rate. Timepoint: Recording the mortality rate for one year after starting plasma therapy. Method of measurement: Patient file information.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hossein Hadinedoushan

Yazd University of Medical Sciences

hhadin2000@gmail.com+98 35 3628 5406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026